文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在加纳的一个艾滋病毒队列中,使用多替拉韦为主的治疗实现病毒学控制缓慢,但免疫和代谢恢复良好。

Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana.

作者信息

Appeaning Mark, Magomere Edwin, Abotsi Alberta Mawulawoe, Amoako Nana Ama Yeboaa, Kouffie Kirk Elorm, Tetteh Becky Ewurama, Quist Bridget Nana Darkoa, Tchopba Christèle Nguepou, Ansa Gloria Akosua, Bonney Evelyn Yayra, Quashie Peter Kojo

机构信息

West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, P.O. Box LG54, Legon, Accra, 23321, Ghana.

Department of Biochemistry Cell and Molecular Biology, School of Biological Sciences, College of Basic and Applied Sciences, University of Ghana, P.O. Box LG54, Legon, Accra, 23321, Ghana.

出版信息

Virol J. 2025 Jul 19;22(1):247. doi: 10.1186/s12985-025-02873-w.


DOI:10.1186/s12985-025-02873-w
PMID:40684209
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12275435/
Abstract

INTRODUCTION: The West African HIV/AIDS epidemic, historically driven by HIV-1 CRF02_AG, other recombinant forms and HIV-2, remains less researched for various preventive and therapeutic interventions. We established the WACCBIP long-term HIV Infection Cohort (WHICH Study) to investigate the dynamics of HIV epidemic in Ghana. This report evaluates viral load dynamics, immune responses, and organ-level metabolic changes following antiretroviral therapy (ART) initiation. METHOD: We collected blood samples, medical, and demographic data from ART-naïve individuals at baseline and six months post-ART, and from ART-experienced individuals at a single time point. Participants, aged 10 years and above, were purposively enrolled from six health facilities. Laboratory analyses included viral load, CD4 and CD8 counts, co-infection screening (hepatitis B/C, syphilis), liver and kidney function tests, haemoglobin estimation, and HIV-1/2 typing. Chi-square and logistic regression analyses were used to assess associations between participant demographics and clinical data with uncontrolled viremia and immune recovery. RESULTS: A total of 426 participants were recruited, comprising 159 ART-naïve and 267 ART-experienced individuals, with a mean age of 41.5 years. Median ART duration for ART-experienced was greater than 5 years. Infections included HIV-1 (78.6%), HIV-2 (2.1%), and dual HIV-1&2 (19.2%). Common comorbidities were anaemia (54.9%), hepatitis B (9.5%), and hypertension (8.2%). Most participant (97.9%) were on dolutegravir-anchored regimen. Among ART-naïve individuals, median viral load decreased from log 5.16 at baseline to log 4.64 copies/mL after six months (p = 0.0156). Median viral load for the ART-experienced arm was log 3.23 copies/mL. Median CD4 count increased from 290 cells/mm³ in ART-naïve participants to 504 cells/mm³ at six-months post-ART (p = 0.0003) and 581 cells/mm³ in ART-experienced participants (p < 0.0001). ART-naïve participants were 19 times more likely to have unsuppressed viral loads at baseline compared to ART-experienced participants. ARTnaïve- participants had significantly decreased odds of immune recovery (aOR = 0.35, 95% CI: 0.140-0.85, p = 0.021), as did those with low CD4/CD8 ratio (aOR = 0.06, 95% CI: 0.02-0.20; p < 0.001). Kidney function and haemoglobin levels were significantly improved six-month post-ART among the ART-naïve group. CONCLUSION: This study highlights the significant reduction in viral load and improved immune recovery following ART initiation despite uncontrolled viremia in a subset of participants. This cohort presents an opportunity to study Ghana's local HIV epidemic, including HIV-1 and HIV-2, and impact of ART on disease progression.

摘要

引言:西非的艾滋病毒/艾滋病疫情,历史上由HIV-1 CRF02_AG、其他重组形式和HIV-2驱动,在各种预防和治疗干预方面的研究仍然较少。我们建立了WACCBIP长期艾滋病毒感染队列(WHICH研究),以调查加纳艾滋病毒疫情的动态。本报告评估了抗逆转录病毒治疗(ART)开始后病毒载量动态、免疫反应和器官水平的代谢变化。 方法:我们在基线和ART后六个月收集了未接受过ART治疗个体的血样、医疗和人口统计学数据,并在单一时间点收集了有ART治疗经验个体的数据。年龄在10岁及以上的参与者从六个卫生设施中有意招募。实验室分析包括病毒载量、CD4和CD8计数、合并感染筛查(乙型/丙型肝炎、梅毒)、肝肾功能测试、血红蛋白估计以及HIV-1/2分型。使用卡方检验和逻辑回归分析来评估参与者人口统计学和临床数据与未控制的病毒血症和免疫恢复之间的关联。 结果:共招募了426名参与者,包括159名未接受过ART治疗的个体和267名有ART治疗经验的个体,平均年龄为41.5岁。有ART治疗经验者的ART中位持续时间超过5年。感染包括HIV-1(78.6%)、HIV-2(2.1%)和HIV-1&2双重感染(19.2%)。常见合并症包括贫血(54.9%)、乙型肝炎(9.5%)和高血压(8.2%)。大多数参与者(97.9%)采用以多替拉韦为基础的治疗方案。在未接受过ART治疗的个体中,病毒载量中位数从基线时的log 5.16降至六个月后的log 4.64拷贝/毫升(p = 0.0156)。有ART治疗经验组的病毒载量中位数为log 3.23拷贝/毫升。未接受过ART治疗的参与者的CD4计数中位数从290个细胞/立方毫米增加到ART后六个月时的504个细胞/立方毫米(p = 0.0003),有ART治疗经验的参与者增加到581个细胞/立方毫米(p < 0.0001)。与有ART治疗经验的参与者相比,未接受过ART治疗的参与者在基线时病毒载量未得到抑制的可能性高19倍。未接受过ART治疗的参与者免疫恢复的几率显著降低(调整后比值比 = 0.35,95%置信区间:0.140 - 0.85,p = 0.021),CD4/CD8比值低的参与者也是如此(调整后比值比 = 0.06,95%置信区间:0.02 - 0.20;p < 0.001)。未接受过ART治疗的组在ART后六个月时肾功能和血红蛋白水平显著改善。 结论:本研究强调了尽管部分参与者存在未控制的病毒血症,但ART开始后病毒载量显著降低且免疫恢复得到改善。该队列提供了一个研究加纳当地艾滋病毒疫情(包括HIV-1和HIV-2)以及ART对疾病进展影响的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5d/12275435/0e91f24c006c/12985_2025_2873_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5d/12275435/032fd78c65ac/12985_2025_2873_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5d/12275435/936fb64631f7/12985_2025_2873_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5d/12275435/0e91f24c006c/12985_2025_2873_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5d/12275435/032fd78c65ac/12985_2025_2873_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5d/12275435/936fb64631f7/12985_2025_2873_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5d/12275435/0e91f24c006c/12985_2025_2873_Fig1_HTML.jpg

相似文献

[1]
Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana.

Virol J. 2025-7-19

[2]
Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial.

Lancet HIV. 2025-6

[3]
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (DEFT): an open-label, randomised, phase 3b/4 trial.

Lancet HIV. 2024-7

[4]
Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon.

J Int Assoc Provid AIDS Care. 2024

[5]
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Cochrane Database Syst Rev. 2014-5-22

[6]
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia.

J Acquir Immune Defic Syndr. 2025-5-1

[7]
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.

Cochrane Database Syst Rev. 2006-7-19

[8]
Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.

BMC Infect Dis. 2021-2-26

[9]
Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.

J Infect Dis. 2025-3-17

[10]
Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.

Viruses. 2024-5-1

本文引用的文献

[1]
High prevalence of hepatitis C virus infection among adolescents and young adults attending HIV and sexual health clinics.

Int J STD AIDS. 2025-3

[2]
Characteristics of Hepatitis B Virus, Hepatitis C Virus, and Syphilis Coinfection in People With HIV/AIDS Contracted Through Different Sources: Retrospective Study.

JMIR Public Health Surveill. 2024-2-27

[3]
Dolutegravir based therapy showed CD4 T cell count recovery and viral load suppression among ART naïve people living with HIV AIDS: a pilot evaluation.

Sci Rep. 2024-2-8

[4]
The burden of non-communicable diseases among people living with HIV in Sub-Saharan Africa: a systematic review and meta-analysis.

EClinicalMedicine. 2023-10-5

[5]
HIV-Host Cell Interactions.

Cells. 2023-5-9

[6]
T cells in health and disease.

Signal Transduct Target Ther. 2023-6-19

[7]
Prevalence of and factors associated with late diagnosis of HIV in Malawi, Zambia, and Zimbabwe: Results from population-based nationally representative surveys.

PLOS Glob Public Health. 2022-2-22

[8]
Immune response to ART initiation in advanced HIV infection.

HIV Med. 2023-6

[9]
Sero-prevalence and associated factors of sexually transmitted infections among youth-friendly services Attendees.

PLoS One. 2023

[10]
Molecular Epidemiology of HIV-1 in Ghana: Subtype Distribution, Drug Resistance and Coreceptor Usage.

Viruses. 2022-12-31

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索